Two infants developed atypical hemolytic uremic syndrome (aHUS) caused by mutations in the EXOSC3 gene and subsequent COVID-19 infections, as described in a recent case report. The cases, which are unusual in that they do not involve an imbalance of the immune system’s complement pathway, may offer insights into new…
News
A diagnosis of atypical hemolytic uremic syndrome (aHUS) was delayed in a woman with a history of advanced, but treated, cancer due to several confounding factors partly related to that cancer, according to a case report from the U.S. While the woman also had anemia and poor kidney function, two hallmarks…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Soliris (eculizumab) safely and effectively treated children with atypical hemolytic uremic syndrome (aHUS) in a real-world setting, according to a post-marketing surveillance study of pediatric patients in Japan. Notably, nearly three-quarters of the children experienced normalization of all blood parameters in a median of three weeks’ time, the…
A 30-year-old man is thought to have developed atypical hemolytic uremic syndrome (aHUS) after being vaccinated for influenza, as described in a recent case report. “Further studies may be needed to stratify such patients to weigh the risks and benefits of influenza vaccination,” its authors…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
Soliris (eculizumab) maintenance therapy administered every three weeks — instead of the biweekly standard regimen — was sufficient to normalize blood parameters and prevent disease recurrence for at least three years in a 4-year-old boy with atypical hemolytic uremic syndrome (aHUS), a case study reported. Individualized Soliris dosing was…
The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues in a nod to its increased use during the ongoing COVID-19 pandemic. NORD’s report card project began seven…
Genetic testing identified a rare mutation in the complement factor B (CFB) gene that, together with an array of laboratory tests, led to a man being diagnosed with atypical hemolytic uremic syndrome (aHUS). While the CFB mutation left the man genetically predisposed to aHUS, the doctor at Baton Rouge Medical Center in…
Plasma exchange may be doing more harm than good for people with atypical hemolytic uremic syndrome (aHUS), a small study suggests. Specifically, the treatment was found to increase the activation of the complement system — a part of the immune system that is already overly active in aHUS patients.
Recent Posts
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent
- Early Soliris use boosts kidney recovery, cuts dialysis need in aHUS
- Dual therapy benefits man with aHUS, Castleman disease
- Pregnancy triggers aHUS with lung issues in woman: Case report